Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome
Go back to Stoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 240.98 -2.12 (0.87%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $243.10 | 52 Week High | $333.65 | |||
| Open | $242.02 | 52 Week Low | $223.02 | |||
| Day High | $243.32 | P/E | 30.86 | |||
| Day Low | $240.13 | EPS | $7.81 | |||
| Volume | 812,898 | |||||
| (NASDAQ: STOK) | Delayed: 25.68 -0.93 (3.49%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $26.61 | 52 Week High | $ | |||
| Open | $26.83 | 52 Week Low | $ | |||
| Day High | $27.22 | P/E | N/A | |||
| Day Low | $25.31 | EPS | $ | |||
| Volume | 2,257,815 | |||||



